Follow

BioStock: Emission tar Dicots potenskandidat in i klinik

20 January 2023 - 08:15

Läkemedelskandidaten LIB-01 har potential att bli nästa generation potensläkemedel, i alla fall om man frågar Uppsalabaserade Dicot. Efter lovande prekliniska data ska nu nästa stora steg i utvecklingen tas, kliniska fas I-studier. Bolaget genomför just nu en unitemission om initialt cirka 55 Mkr för att finansiera detta viktiga steg.

Läs hela artikeln på biostock.se:

https://www.biostock.se/2023/01/emission-tar-dicots-potenskandidat-in-i-klinik/

Detta är ett pressmeddelande från BioStock – Connecting Innovation & Capitalhttps://www.biostock.se

Provided by: Cision
Spotlight Stock Market (Sweden)
Dicot AB
Dicot is a pharmaceutical company with focus on the development of pharmaceuticals for the treatment of various sexual dysfunctions. The products are sold under various trademarks, and primarily treat erection problems among men. The main substance is formed from libiguin, a substance from the root of a particular tree found on Madagascar....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More